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Results: Both CH and glycine were able to counteract the
zymosan-induced ear swelling at 3 h after zymosan injection in
a concentration depending manner. This effect was accompanied
by a concentration dependent increase in the levels of free serum
glycine and a decrease in the production of pro-inﬂammatory cy-
tokines. The CH effects were less pronounced compared to the
glycine effects.
Conclusions: The present study indicates that CH is able to
display an anti-inﬂammatory activity. The reduction of pain by CH,
as indicated in several clinical studies in patients with OA, could
at least partially origin from the anti-inﬂammatory capacity of CH.
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Purpose: The management of knee Osteoarthritis (KOA) is
presently focused on reducing the level of pain and disability. Mus-
cle weakness and proprioception difﬁculties have been related to
KOA severity, level of pain and disability and are an integral focus
of the therapeutic program for KOA patients. A novel biomechan-
ical device (APOS system) designated to strengthen and train
neuromuscular control was shown to reduce knee adduction mo-
ment. The purpose of the current study was to investigate the
clinical effect of this biomechanical device on patients with KOA.
Methods: 47 patients with bilateral KOA were enrolled to the study.
Patient underwent a gait test and completed the WOMAC Index
and the SF-36 health survey at baseline and after 12 weeks. The
biomechanical device was individually calibrated to each patient
as to allow training under reduced pain. Patients were instructed
to walk with the device on a daily basis for a period of 12 weeks.
Spatio-temporal parameters were used to identify changes in gait
patterns and the questionnaires were used to identify changes in
the reported level of pain, function and quality of life.
Results: Gait velocity, step length and single limb support in-
creased signiﬁcantly following the 3 months of treatment (10%, 6%
Abstract 518 – Figure 1. Production of endogenous hyaluronic synthesis from human synoviocytes with varying intervention concentrations at two time periods.
and 1%, respectively). In addition, WOMAC-Pain and WOMAC-
Function signiﬁcantly decreased (22% and 24%, respectively),
and SF-36 score signiﬁcantly increased (14%) (P<0.001 for all
parameters).
Conclusions: Our results suggest an overall improvement in the
gait pattern, level of pain and functional condition of patients with
KOA following 12 weeks of treatment with the novel biomechanical
device.
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Purpose: Hyaluronic acid (HA) is a heteropolysaccharide present
in synovial ﬂuid and in extracellular matrix of cartilage. HA is
synthesized by human synoviocytes and chondrocytes, and is re-
sponsible for the viscosity of articular synovial ﬂuid. Synovial ﬂuid
has mechanical properties and biochemical properties such as: 1)
Inhibition of prostaglandin E2 and synthesis of nitric oxide (NO)
induced by IL-1. 2) Protection against proteoglycan depletion. 3)
Protection against cytotoxicity induced by oxygen-derived free rad-
icals and NO-induced apoptosis. 4) Affects on leukocyte function.
5) The suppression of cartilage-matrix degradation. 6) Stimula-
tion of the synthesis of endogenous HA. In patients with OA,
the concentration of endogenous HA in synovial ﬂuid decreases
signiﬁcantly. Intra-articular administration of exogenous HA is a
therapeutic option currently in use to treat grades II-III knee OA
patients. We therefore conceived the present study, to ﬁnd out
whether the compounds IB0004 (a natural rooster comb extract
rich in HA) and ID386 (avian hydrolyzed collagen with low HA
content) stimulate the synthesis of endogenous hyaluronic acid in
human osteoarthritic synoviocytes.
Methods: To study the effect of IB0004 and ID386, Human syn-
oviocytes from OA synovial tissue were prepared by enzymatic
digestion, isolated, and cultivated in RPMI supplemented with 10%
